Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Revvity, Inc. Common Stock (NY:RVTY)

93.83 +0.57 (+0.61%)
Streaming Delayed Price Updated: 1:06 PM EDT, May 19, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Revvity, Inc. Common Stock

< Previous 1 2 3 4 5 Next >
Revvity’s EUROIMMUN Unveils New Fully Automated Instrument for Specialty Testing
From Revvity
Via Business Wire
3 Mid-Cap Stocks with Questionable Fundamentals
Many investors pay attention to mid-cap stocks because they have established business models and expansive market opportunities. However, their paths to becoming $100 billion corporations are ripe with... 
Via StockStory
Stay informed with the top movers within the S&P500 index on Wednesday.
Join us in exploring the top gainers and losers within the S&P500 index one hour before the close of the markets on Wednesday as we examine the latest happenings in today's session. 
Via Chartmill
Earnings Preview For Revvity
Via Benzinga
Assessing Revvity: Insights From 6 Financial Analysts
Via Benzinga
What's going on in today's session: S&P500 movers
Curious about the top performers within the S&P500 index in the middle of the day on Wednesday? Dive into the list of today's session's top gainers and losers for a comprehensive overview. 
Via Chartmill
Which S&P500 stocks are gapping on Wednesday?
Looking for the S&P500 stocks that are experiencing notable gaps on Wednesday? Find out which stocks are gapping up and gapping down in the S&P500 index during today's session. 
Via Chartmill
Repligen, Bruker, Agilent, Medpace, and Revvity Shares Skyrocket, What You Need To Know
A number of stocks jumped in the afternoon session after the major indices popped (Nasdaq +3.4%, S&P 500 +2.5%) in response to the positive outcome of U.S.-China trade negotiations, as both sides... 
Via StockStory
Topics Government Stocks World Trade
Exposures Political Tariff US Equities
RVTY Q1 Earnings Call: Resilient Performance Amid Academic and Tariff Headwinds, Software and Diagnostics Shine
Life sciences company Revvity (NYSE:RVTY) reported Q1 CY2025 results beating Wall Street’s revenue expectations, with sales up 2.3% year on year to $664.8 million. The company’s full-year revenue... 
Via StockStory
Topics Economy World Trade
Exposures Supply Chain Tariff
3 S&P 500 Stocks in the Doghouse
The S&P 500 (^GSPC) is home to the biggest and most well-known companies in the market, making it a go-to index for investors seeking stability. But not all large-cap stocks are created equal - some... 
Via StockStory
Topics Stocks
Exposures US Equities
1 Safe-and-Steady Stock with Exciting Potential and 2 to Avoid
Low-volatility stocks may offer stability, but that often comes at the cost of slower growth and the upside potential of more dynamic companies. 
Via StockStory
Revvity to Present at Upcoming Investor Conferences
From Revvity
Via Business Wire
What's going on in today's pre-market session: S&P500 movers
Stay updated with the S&P500 stocks that are on the move in today's pre-market session. 
Via Chartmill
Life Science Tools Maker Revvity Delivers Strong Q1 Earnings Despite Evolving Macroeconomic Backdrop
Revvity posts strong Q1 results with Life Sciences and Diagnostics growth, lifts 2025 sales guidance, and expects higher adjusted operating margins. 
Via Benzinga
Revvity Q1 Earnings Surpass Street Estimates, Investors Cheer 2025 Revised Revenue Guidance
For the full year, Revvity raised its revenue guidance to a range of $2.83 billion to $2.87 billion to reflect recent changes in foreign currency exchange rates. 
Via Stocktwits
Revvity (NYSE:RVTY) Posts Better-Than-Expected Sales In Q1, Full-Year Outlook Slightly Exceeds Expectations
Life sciences company Revvity (NYSE:RVTY) announced better-than-expected revenue in Q1 CY2025, with sales up 2.3% year on year to $664.8 million. The company’s full-year revenue guidance of $2.85... 
Via StockStory
Revvity Announces Financial Results for the First Quarter of 2025
From Revvity
Via Business Wire
Revvity (RVTY) Q1 Earnings Report Preview: What To Look For
Life sciences company Revvity (NYSE:RVTY) will be reporting results tomorrow before market hours. Here’s what investors should know. 
Via StockStory
Topics Artificial Intelligence
Exposures Artificial Intelligence
Earnings Scheduled For April 28, 2025
Via Benzinga
Revvity Board Declares Quarterly Dividend
From Revvity
Via Business Wire
3 Cash-Producing Stocks Skating on Thin Ice
A company that generates cash isn’t automatically a winner. Some businesses stockpile cash but fail to reinvest wisely, limiting their ability to expand. 
Via StockStory
Get insights into the top movers in the S&P500 index of Monday's pre-market session.
Wondering what's happening in today's pre-market session? Stay tuned for the latest updates on S&P500 stock movements. 
Via Chartmill
Revvity to Hold Earnings Call on Monday, April 28, 2025
From Revvity
Via Business Wire
What's Going On With Revvity Stock Today?
Revvity's stock rose after FDA approval of its Auto-Pure 2400 platform integrated with the T-SPOT.TB test, improving latent TB detection efficiency in labs. 
Via Benzinga
Exposures Product Safety
Revvity Secures FDA Approval for Improved Automated Latent Tuberculosis Test
From Revvity
Via Business Wire
1 Healthcare Stock to Target This Week and 2 to Turn Down
Personal health and wellness is one of the many secular tailwinds for healthcare companies. Despite the rosy long-term prospects, short-term headwinds such as COVID inventory destocking have harmed the... 
Via StockStory
Topics Stocks
Exposures COVID-19 US Equities
Is Revvity Gaining or Losing Market Support?
Via Benzinga
How Tariffs Are Rocking The 'Bubblegum And Shoestring' Medical Supply Chain
Uncertainty has cast a pall over medical stocks, which are taking a "wait-and-see" approach to Trump's tariffs. 
Via Investor's Business Daily
Topics Government
Exposures Political
Maryland Rep. April McClain Delaney Sold Over $54K Worth of A.O. Smith Stock: Here's What You Should Know
Via Benzinga
Revvity Expands Alliance with Genomics England to Drive Research into Newborn Genomic Sequencing in England
From Revvity
Via Business Wire
< Previous 1 2 3 4 5 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.